Taysha Gene Therapies Inc

Research Taysha Gene Therapies Inc (TSHA) on Bullrun: market cap USD 1.93B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTSHA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.93B
• Financial periodFY2025
• RevenueUSD 9.77M
• Revenue growth17.3%
• Net income-USD 109.00M
• Free cash flow-USD 93.83M

Valuation Snapshot

latest market cap is USD 1.93B.

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency;

Frequently asked questions

What is Taysha Gene Therapies Inc's market cap?

Taysha Gene Therapies Inc's market capitalization is USD 1.93B.

What does Taysha Gene Therapies Inc do?

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.